Europe Nuclear Medicine Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Europe Nuclear Medicine Market is Segmented by Diagnostics (Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET)), Therapeutics (Alpha Emitters, Beta Emitters, and Brachytherapy), Application (Cardiology, Neurology, Oncology, and Other Applications) and Geography (Germany, UK, France, Italy, Spain, and Rest of Europe). The Report Offers the Value (in USD Million) for the Above Segments.

Europe Nuclear Medicine Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Europe Nuclear Medicine Market Size

View Global Report
Europe Nuclear Medicine Market  Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Market Size (2025) USD 4.95 Billion
Market Size (2030) USD 7.97 Billion
CAGR (2025 - 2030) 10.00 %
Market Concentration Medium

Major Players

Europe Nuclear Medicine Market  Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Europe Nuclear Medicine Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Europe Nuclear Medicine Market Analysis

The Europe Nuclear Medicine Market size is estimated at USD 4.95 billion in 2025, and is expected to reach USD 7.97 billion by 2030, at a CAGR of 10% during the forecast period (2025-2030).

The COVID-19 pandemic posed serious challenges to European healthcare systems and has largely been controlled by drastically cutting down in- and outpatient services for diseases and implementing infection prevention and control measures. For instance, according to an article published by the European Journal of Nuclear Medicine and Molecular Imaging in June 2022, the pandemic has been observed to have impacted nuclear medicine education in most countries (84%). This was broken down into affecting different employment groups as follows: technologists (78%), radio pharmacists (59%), physicists (67%), and physicians (74%). In addition, as per the same source, according to the survey, 12/32 countries reported that research and development activities were kept on hold due to the restrictions imposed by the government due to COVID-19, which comprised 38% of sponsored trials, 28% of aggregated therapeutic research, and 39% of diagnostic research. This mostly happened in Northern European countries and a few Eastern European countries. Thus, the COVID-19 pandemic significantly impacted the market during the early phase; however, as the pandemic has subsided currently, the market is expected to have stable growth during the forecast period of the study.

The studied market is expected to grow significantly during the study period due to the increasing incidence of cancer and cardiac diseases and rising SPECT and PET applications.

The rising prevalence of cardiac disease and cancer is the key factor driving the demand for the nuclear medicine market in Europe. For instance, according to the British Heart Foundation England Factsheet, published in August 2022, about 7.6 million people in the United Kingdom live with heart or circulatory diseases. Also, as per the same source, it is estimated that in the United Kingdom, more than half of the people will get a heart or circulatory condition in their lifetime, and around twice as many people are living with heart and circulatory diseases in the United Kingdom than with cancer and Alzheimer's disease combined. It is also estimated that around 48,000 people under 75 in the United Kingdom die from heart and circulatory diseases each year. Thus, the rising burden of cardiovascular disease is expected to increase the demand for nuclear medicine for diagnosing, assessing, and evaluating coronary artery diseases and cardiomyopathy and identifying possible damage to the heart from chemotherapy or radiotherapy, thereby propelling the market growth.

Additionally, as per the data published by Macmillan Cancer Support in October 2022, It is estimated that there are currently 3 million people living with cancer in the United Kingdom, and it is expected to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Thus, the rising burden of cancer among the population is expected to increase the demand for nuclear medicine that helps physicians in detecting tumors and their spread in the area as well as the radioactive molecules (drug) that helps to kill the cancer cells in the body, thereby fueling the market growth.

Hence, due to the factors above, such as the rising prevalence of cardiovascular diseases and cancer, the market is expected to experience growth during the forecast period of the study. However, strict regulatory guidelines are expected to hinder market growth over the forecast period.

Europe Nuclear Medicine Industry Overview

The Europe Nuclear Medicine market is highly competitive, with the presence of a large number of players. There is high competition among the players in the global nuclear medicine market. Additionally, big players in the pharmaceutical and biotechnology industries are leveraging their huge capital reserves to venture into this market, further increasing the competition. Some of the major players in the market are Advanced Accelerator Applications, Bracco Imaging, Cardinal Health, Curium Pharma, GE Healthcare, Merck KGaA (Sigma-Aldrich), Nordion Inc., and Siemens Healthineers AG.

Europe Nuclear Medicine Market Leaders

  1. Cardinal Health

  2. Curium Pharma

  3. GE Healthcare

  4. Novartis AG (Advanced Accelerator Applications)

  5. Siemens Healthineers AG

  6. *Disclaimer: Major Players sorted in no particular order
Europe Nuclear Medicine Market  Concentration
Need More Details on Market Players and Competiters?
Download PDF

Europe Nuclear Medicine Market News

  • In June 2022, Curium submitted its Marketing Authorization Application for [18F]-DCFPyL for treating multiple stages of prostate cancer disease to the European Medicines Agency.
  • In May 2022, Turku PET Centre, Finland, introduced a new total-body Positron Emission Tomography (PET) scanner, a new generation of medical imaging devices. The device offers novel methods for studying diseases that affect the entire body, such as diabetes, coronary artery disease, and multiple sclerosis.

Europe Nuclear Medicine Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidence of Cancer and Cardiac Ailments
    • 4.2.2 Increasing SPECT and PET Applications
  • 4.3 Market Restraints
    • 4.3.1 Strict Regulatory Guidelines
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value in USD million)

  • 5.1 By Diagnostics
    • 5.1.1 Single Photon Emission Computed Tomography (SPECT)
    • 5.1.2 Positron Emission Tomography (PET)
  • 5.2 By Therapeutics
    • 5.2.1 Alpha Emitters
    • 5.2.2 Beta Emitters
    • 5.2.3 Brachytherapy
  • 5.3 By Application
    • 5.3.1 Cardiology
    • 5.3.2 Neurology
    • 5.3.3 Oncology
    • 5.3.4 Other Applications
  • 5.4 Geography
    • 5.4.1 Germany
    • 5.4.2 United Kingdom
    • 5.4.3 France
    • 5.4.4 Italy
    • 5.4.5 Spain
    • 5.4.6 Rest of Europe

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Advanced Accelerator Applications
    • 6.1.2 Bracco Imaging SpA
    • 6.1.3 Cardinal Health Inc.
    • 6.1.4 Curium Pharma
    • 6.1.5 GE Healthcare
    • 6.1.6 Merck KGaA (Sigma-Aldrich)
    • 6.1.7 Nordion Inc.
    • 6.1.8 Siemens Healthineers AG
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Europe Nuclear Medicine Industry Segmentation

As per the report's scope, nuclear medicine falls under molecular imaging, which involves using a very small amount of radioactive material (radiopharmaceuticals) to diagnose and treat disease. In nuclear medicine imaging, the radioisotopes are detected by special types of cameras attached to the computer, which in turn, provide precise pictures of the area of the body examined. The Europe Nuclear Medicine Market is segmented by Diagnostics (Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET)), Therapeutics (Alpha Emitters, Beta Emitters, and Brachytherapy), Application (Cardiology, Neurology, Oncology, and Other Applications) and Geography (Germany, United Kingdom, France, Italy, Spain, and Rest of Europe). The report offers the value (in USD million) for the above segments.

By Diagnostics Single Photon Emission Computed Tomography (SPECT)
Positron Emission Tomography (PET)
By Therapeutics Alpha Emitters
Beta Emitters
Brachytherapy
By Application Cardiology
Neurology
Oncology
Other Applications
Geography Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Need A Different Region or Segment?
Customize Now

Europe Nuclear Medicine Market Research FAQs

How big is the Europe Nuclear Medicine Market?

The Europe Nuclear Medicine Market size is expected to reach USD 4.95 billion in 2025 and grow at a CAGR of 10% to reach USD 7.97 billion by 2030.

What is the current Europe Nuclear Medicine Market size?

In 2025, the Europe Nuclear Medicine Market size is expected to reach USD 4.95 billion.

Who are the key players in Europe Nuclear Medicine Market?

Cardinal Health, Curium Pharma, GE Healthcare, Novartis AG (Advanced Accelerator Applications) and Siemens Healthineers AG are the major companies operating in the Europe Nuclear Medicine Market.

What years does this Europe Nuclear Medicine Market cover, and what was the market size in 2024?

In 2024, the Europe Nuclear Medicine Market size was estimated at USD 4.46 billion. The report covers the Europe Nuclear Medicine Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Europe Nuclear Medicine Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Small Signal Diode Industry Report

Statistics for the 2025 Europe Nuclear Medicine market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Europe Nuclear Medicine analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.